myirislogo
21 October, 2019 10:27 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Tata Motors 136.70 1.05
State Bank O 269.65 1.58
Tata Stl 359.90 1.19
Tata Power 60.05 0.42
Reliance 1415.30 1.37
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Shasun Pharmaceuticals Limited
Shasun Pharmaceuticals Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:24552NSE:SHASUNPHARBloomberg:SAPH@INReuters:SHAS.BO
Market Lot: 1Face Value: 2ISIN Demat: INE317A01028
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
22-JAN-16 Sun Pharmaceutical Industries announced that the company has received order under the Competition Act, 2002 from the Competition Commission of India (CCI) approving the proposed transactio 16-NOV-15 Shasun Pharmaceuticals, a pharmaceutical contracting organization, today announced that it has received approval from the United States Food & Drug Administration (USFDA) for Carisoprodol Tablets USP 250 mg and 350 mg. 23-JUL-15 Shasun P...   More..
Business Profile Future Plans
CEO Talk
Shasun Chemicals and Drugs Ltd, while focusing on the bulk drugs business, expects increased contribution from the contract research business. The bulk drugs business, including the biotech sector, will continue to be its major focus in the years to come.   S. Vimal Kumar
One To One
Recent news
Previous

 


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Sep-2015(6)31-Mar-2015 (12)31-Mar-2014 (12)
Net sales 5020.6010243.108816.20
Other Income59.10139.20122.70
Total Income5079.7010382.308938.90
Cost of goods sold4679.709655.008452.70
OPBDIT400.00727.30486.20
PAT187.20413.40352.30
Gross Block---
Equity capital134.50120.30113.30
EPS (Rs.)-6.946.22
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-10.12 - 56.417.33 - 15.14
Debt / Equity (x)---
Operating margin (% of OI) 7.9 7.0 5.4
Net margin (% of OI) 3.7 4.0 3.9
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Batra Centre
28 Sardar Patel Road
3rd and 4th floor
Guindy
Chennai
Tamil Nadu-600 032
PHONE
(044) 4344 6700
FAX
(044) 2235 0924/ 2235 0278
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer